Matthew A. Marx
YOU?
Author Swipe
View article: Discovery and In Vitro Reconstitution of Closoxazole Biosynthesis from <i>Pyxidicoccus fallax</i>
Discovery and In Vitro Reconstitution of Closoxazole Biosynthesis from <i>Pyxidicoccus fallax</i> Open
Benzoxazoles are important structural components of both bioactive natural products and pharmaceutical active ingredients. In this study, a putative benzoxazole gene cluster originating from the myxobacterium Pyxidicoccus fallax is investi…
View article: Supplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S4 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
View article: Supplementary Figure S7 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S7 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S7 shows the improved antiproliferative activity observed with the MRTX0902/avutometinib combination in KRAS-MAPK pathway mutant models, LN229 (PTPN11 A72S) and NCI-H1435 (NF1 K615N).
View article: Supplementary Table S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Table S4 shows the antitumor activity of MRTX0902 and osimertinib in human EGFR-mutant tumor cell line-derived xenograft models.
View article: Data from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Data from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
KRAS is the most frequently mutated oncogene in human cancer and facilitates uncontrolled growth through hyperactivation of the receptor tyrosine kinase (RTK)/mitogen-activated protein kinase (MAPK) pathway. The Son of Sevenless hom…
View article: Supplementary Figure S3 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S3 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S3 details the antitumor effects and gene set enrichment analysis data associated with coadministration of MRTX0902 and adagrasib in KRAS G12C-mutant human tumor xenograft models.
View article: Supplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).
View article: Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S8 details the antitumor effects associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
View article: Supplementary Table S3 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S3 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Table S3 displays the various genetic co-alterations present in human KRAS G12C-mutant tumor cell line-derived and patient-derived xenograft models evaluated.
View article: Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S5 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the murine CT26 (KRAS G12C-mutant) model.
View article: Supplementary Table S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Table S2 shows the antitumor activity of MRTX0902 and adagrasib in a panel of human KRAS G12C-mutant tumor cell line-derived and patient-derived xenograft models.
View article: Supplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S2 shows the antitumor activity of MRTX0902 in the LN229 (PTPN11 A72S-mutant) model, with tumor growth inhibition data displayed in Figure S2A and ERK phosphorylation graphed in Figure S2B.
View article: Supplementary Table S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Table S5 details the antitumor activity of MRTX0902 and avutometinib in human KRAS-MAPK pathway mutant tumor cell line-derived xenograft models.
View article: Supplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Figure S1 details the genetic vulnerabilities and modifiers of response associated with combination treatment of MRTX0902 with adagrasib in the KRAS G12C-mutant MIA PaCa-2 (S1A, S1B, S1D, and S1E) and LU99 (S1C) cell lines
View article: Supplementary Materials and Methods from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Materials and Methods from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Materials and Methods section includes detailed protocols for the following: Experimental Preparation of MRTX0902 and Avutometinib, SOS1 Biochemical Binding Assay, SOS1 and SOS2 Functional Assays, KRAS-SOS1 Protein-Protiein I…
View article: Supplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading Open
Supplementary Table S1 details the efficacy of MRTX0902 in a panel of cancer cell lines.
View article: Supplementary Figure S3 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S3 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Thermal shift PRMT5 inhibitor data
View article: Supplementary Table S4 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Table S4 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Treatment-related treatment-emergent adverse events by preferred term and maximum grade safety population
View article: Supplementary Figure S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Supplemental biochemical and cellular characterization of MRTX1719
View article: Supplementary Table S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Table S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
PTMScan data tables
View article: Supplementary Figure S5 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S5 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Co-culture experiments with MTAP-expressing fibroblasts
View article: Supplementary Figure S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
SDMA and MTAP IHC TMA data
View article: Supplementary Materials and Methods from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Materials and Methods from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Materials and methods related to supplemental data
View article: Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Supplemental pharmacodynamic effects of MRTX1719 in patients
View article: Supplementary Figure S3 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S3 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Thermal shift PRMT5 inhibitor data
View article: Supplementary Table S4 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Table S4 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Treatment-related treatment-emergent adverse events by preferred term and maximum grade safety population
View article: Supplementary Table S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Table S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Hematological parameters in CD-1 mice treated with MRTX11719
View article: Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
Supplemental pharmacodynamic effects of MRTX1719 in patients
View article: Supplementary Figure S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Figure S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
SDMA and MTAP IHC TMA data
View article: Supplementary Table S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Supplementary Table S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer Open
PTMScan data tables